The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / SM04690 Promising for Knee OA

SM04690 Promising for Knee OA

March 27, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

SM04690 is a small-molecule inhibitor of the Wnt pathway currently in clinical trials to evaluate its use managing knee osteoarthritis (OA). The treatment is an intra-articular injection being developed as a disease-modifying osteoarthritis drug (DMOAD). Preclinical data suggest this agent has a dual action mechanism, with three joint health effects: cartilage generation, slowing of cartilage breakdown and inflammation reduction. Presently, no DMOADs are approved by the U.S. Food and Drug Administration.1

You Might Also Like
  • OA Patient-Reported Outcomes Positive for Intra-Articular Injection
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial
  • OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients
Also By This Author
  • Upadacitinib + Methotrexate & Other csDMARDs in RA Patients

In a 24-week, phase 2b study, SM04690 was compared with placebo in patients (N=700) with moderate to severe knee OA. A single intra-articular SM04690 injection led to significant pain reduction and function improvement, as well as better patient global assessment scores compared with placebo-treated patients. In a prior, phase 2a study of 450 patients, SM04690-treated patients showed significant improvements in medial joint space width compared with placebo-treated patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Next Steps
In the first half of 2019, the STRIDES phase 3 studies of SM04690 are expected to begin. The six-month STRIDES 1 study will compare SM04690 with placebo, assessing pain as the primary endpoint as measured by the Daily Pain Numerical Rating Scale (NRS). A key secondary endpoint is joint function measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function subscore. The 12-month, STRIDES X-ray study will evaluate SM04690’s effects on the NRS and WOMAC scores. The study will also assess disease changes in medial joint space width measured by X-ray.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Samumed LLC. News release: Samumed announces positive end of phase 2 meeting with FDA for SM04690 in knee osteoarthritis. 2019 Feb 28.

Filed Under: Drug Updates Tagged With: disease-modifying osteoarthritis drug (DMOAD), joint injection, knee, Knee Osteoarthritis (OA), Osteoarthritis, SM04690

You Might Also Like:
  • OA Patient-Reported Outcomes Positive for Intra-Articular Injection
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial
  • OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients
  • FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.